Review article: Functional dyspepsia and pregnancy—Effects and management in a special population.
Published In: Alimentary Pharmacology & Therapeutics, 2023, v. 57, n. 12. P. 1375 1 of 3
Database: Academic Search Ultimate 2 of 3
Authored By: Liu, Benjamin D.; Starkey, Morgan; Virani, Aleena; Pichette, Sandra L.; Fass, Shira; Song, Gengqing 3 of 3
Abstract
Summary: Background: Around 10% of Americans meet the Rome IV criteria for functional dyspepsia (FD), with a significantly higher rate in women. FD also has a higher prevalence in women below the age of 50, suggesting that women who are affected are likely to be of reproductive age. Unfortunately, there is a lack of research or evidence‐based guidelines on managing FD in pregnancy. Aims and Methods: To address this issue, we aimed to perform a systematic review of the interactions between FD and pregnancy and managing pre‐existing FD in the peripartum and post‐partum phases using current lifestyle, pharmacological, non‐pharmacological and alternative medicine interventions. Results: Due to the lack of Rome IV FD‐specific data in pregnancy, we instead performed a narrative review on how existing FD interventions could be extrapolated to the pregnant population. Where possible we use the highest level of available evidence or official guidelines to answer these questions, which often involves synthesising treatment and safety evidence of these interventions in other diseases during pregnancy. Finally, we highlight current substantial knowledge gaps requiring further research for the safe management of a pregnant patient with pre‐existing FD. Conclusions: Overall, despite the paucity of knowledge of treating FD during pregnancy, providers can mitigate this uncertainty by planning ahead with the patient. Patients should ideally minimise treatment until after breastfeeding. However, interdisciplinary resources are available to ensure that minimal‐risk interventions are maximised, while interventions with more risks, if necessary, are justifiable by both the patient and the care team. Future investigations should continue to elicit the mechanistic relationship between FD and pregnancy while cautiously expanding prospective research on promising and safe therapies in pregnant patients with pre‐existing FD. [ABSTRACT FROM AUTHOR]
Additional Information
- Source:Alimentary Pharmacology & Therapeutics. 2023/06, Vol. 57, Issue 12, p1375
- Document Type:Article
- Subject Area:Biology
- Publication Date:2023
- ISSN:0269-2813
- DOI:10.1111/apt.17534
- Accession Number:163949064
- Copyright Statement:Copyright of Alimentary Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Looking to go deeper into this topic? Look for more articles on EBSCOhost.